PlatOD

PlatOD ambition is to break down the barrier of large-scale production of ex vivo platelets – an alternative to blood donor platelets transfusions – by developing a disruptive device for a key step of the manufacturing process.

The worldwide platelet transfusion market is estimated more than €3 billion. The demand is sustained due to the aging of the population and the increasing prevalence of cancer.

Manufacturing ex vivo platelets combines two steps, the production of megakaryocytes from a source of stem cells and the platelet production from megakaryocytes. Acting on the platelet production step is the solution to render the overall manufacturing process economically viable.

PlatOD is focused on the development of a device to produce functional platelets in a few hours. PlatOD has already moved from a first-generation able to process a small volume to a second-generation microfluidic device, processing a 10-fold higher volume. Based on already identified parameters, the plan is to focus on building the next generation device allowing manufacturing platelets for clinical development.

Ex vivo platelets produced on demand by PlatOD device will be a standardized manufactured product, clean and sterile and as efficient as blood platelets.